# Pfizer's Dividend Freeze Raises Cash Flow Question

> Pfizer's dividend freeze tests cash flow as patent expirations loom.
- Title: Pfizer's Dividend Freeze Raises Cash Flow Question | Shortify
- Summary: Pfizer's dividend freeze tests cash flow as patent expirations loom. Pfizer can maintain its $0.43 quarterly dividend through 2029 but faces thin cash flow…
- Keywords: pfizer, dividend, cash flow, patent expiration, pfe, leverage, free cash flow, payout ratio, operating cash flow, stock price, Pfizer's, Freeze
- Source: 24/7 Wall St. — https://247wallst.com/investing/2026/10/19/pfizers-dividend-freeze-raises-a-bigger-question-about-its-cash-flow
- Author: Chris Lange
- Published: 2026-10-19T15:15:45+00:00
- Read time: 1 min
- Topics: pfizer, dividend, cash flow, patent expiration, pfe, leverage, free cash flow, payout ratio, operating cash flow, stock price
## Pfizer's Dividend Freeze
Pfizer declared its quarterly dividend at $0.43 per share on Oct 6, 2026, the same amount since early 2025.
## Dividend Payout Ratio
The $1.72 annual dividend works out to a payout ratio of 57% to 61% against 2026 EPS guidance of $2.80 to $3.00.
## Cash Flow Shortfall
In 2025, dividends cost $9.77 billion while operating cash flow minus capital spending was $9.08 billion.
## Debt and Leverage
Total debt rose from $35.8 billion in 2022 to $63.2 billion by June 30, 2026, with cash at $976 million.
## Patent Expiration Impact
Generic competition will cost Pfizer $1.1 billion in revenue this year with larger losses from patent expirations coming later.
## CEO's Dividend Commitment
Chief executive Albert Bourla stated Pfizer will maintain the dividend through patent expiration years and grow it after 2029.

> We feel extremely confident that, even in the most stretched scenarios that we are running, we will be able to maintain our dividend. So I want, once and for all, to make that clear to all: the dividend will be maintained, and eventually, after the LOE period, we will start growing it again.
## Comparison to Competitors
Bristol-Myers Squibb raised its dividend to $0.63 per quarter while Merck faced $9.0 billion and $5.7 billion one-time charges.
## Key takeaway

Pfizer can maintain its $0.43 quarterly dividend through 2029 but faces thin cash flow and debt challenges.